Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials

Journal of the National Cancer Institute

Volumn 106, Issue 7, 2014, Pages

  Reeve, Bryce B ^a   Mitchell, Sandra A ^b   Dueck, Amylou C ^c   Basch, Ethan ^a   Cella, David ^d   Reilly, Carolyn Miller ^e   Minasian, Lori M ^b   Denicoff, Andrea M ^b   O'Mara, Ann M ^b   Fisch, Michael J ^f   Chauhan, Cynthia ^g   Aaronson, Neil K ^h   Coens, Corneel ⁱ   Bruner, Deborah Watkins ^e  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c MAYO CLINIC   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e EMORY UNIVERSITY   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g MAYO CLINIC   (United States)

^h NETHERLANDS CANCER INSTITUTE   (Netherlands)

ⁱ European Organisation of Research and Treatment of Cancer   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIA; ANXIETY; ARTICLE; CANCER CHEMOTHERAPY; CANCER THERAPY; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; CONSENSUS DEVELOPMENT; CONSTIPATION; DATA BASE; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DYSPNEA; EVIDENCE BASED MEDICINE; FATIGUE; HUMAN; INSOMNIA; NATIONAL HEALTH ORGANIZATION; NAUSEA; OUTCOME ASSESSMENT; PAIN; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; SELF REPORT; SENSORY NEUROPATHY; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; ADULT; FEMALE; HEALTH STATUS; METHODOLOGY; MILD COGNITIVE IMPAIRMENT; NEOPLASM; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; REVIEW; SEVERITY OF ILLNESS INDEX; STANDARD; TREATMENT OUTCOME; UNITED STATES;

ADULT; ANOREXIA; ANXIETY; CLINICAL TRIALS AS TOPIC; CONSTIPATION; DEPRESSION; DIARRHEA; DYSPNEA; FATIGUE; FEMALE; HEALTH STATUS; HUMANS; MILD COGNITIVE IMPAIRMENT; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); PAIN; PERIPHERAL NERVOUS SYSTEM DISEASES; PREVALENCE; QUALITY OF LIFE; QUESTIONNAIRES; SELF REPORT; SEVERITY OF ILLNESS INDEX; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME; UNITED STATES;

EID: 84905254868     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju129     Document Type: Article

References (65)

1. Edgerly M, Fojo T. Is there room for improvement in adverse event reporting in the era of targeted therapies? J Natl Cancer Inst. 2008;100(4):240-242.
2. Berry DL. Patient-reported symptoms and quality of life integrated into clinical cancer care. Semin Oncol Nurs. 2011;27(3):203-210.
3. Gebbia V, Bellavia G, Ferrau F, Valerio MR. Adherence, compliance and persistence to oral antineoplastic therapy: A review focused on chemotherapeutic and biologic agents. Expert Opin Drug Saf. 2012;11(Suppl 1):S49-S59.
4. Gotay C, Dunn J. Adherence to long-term adjuvant hormonal therapy for breast cancer. Expert Rev Pharmacoecon Outcomes Res. 2011;11(6):709-715.
5. Oberguggenberger A, Hubalek M, Sztankay M, et al. Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs). Breast Cancer Res Treat. 2011;128(2):553-561.
6. Cockle-Hearne J, Faithfull S. Self-management for men surviving prostate cancer: A review of behavioural and psychosocial interventions to understand what strategies can work, for whom and in what circumstances. Psychooncology. 2010;19(9):909-922.
7. Hsiao CP, Loescher LJ, Moore IM. Symptoms and symptom distress in localized prostate cancer. Cancer Nurs. 2007;30(6):E19-E32.
8. Penson DF. Quality of life following prostate cancer treatments. Curr Urol Rep. 2000;1(1):71-77.
9. Singh J, Trabulsi EJ, Gomella LG. The quality-of-life impact of prostate cancer treatments. Curr Urol Rep. 2010;11(3):139-146.
10. Kubrak C, Olson K, Jha N, et al. Nutrition impact symptoms: key determinants of reduced dietary intake, weight loss, and reduced functional capacity of patients with head and neck cancer before treatment. Head Neck. 2010;32(3):290-300.
11. Lokker ME, Offerman MP, van der Velden LA, de Boer MF, Pruyn JF, Teunissen SC. Symptoms of patients with incurable head and neck cancer: prevalence and impact on daily functioning. Head Neck. 2013;35(6):868-876.
12. Gilbertson-White S, Aouizerat BE, Jahan T, Miaskowski C. A review of the literature on multiple symptoms, their predictors, and associated outcomes in patients with advanced cancer. Palliat Support Care. 2011;9(1):81-102.
13. Johnsen AT, Petersen MA, Pedersen L, Groenvold M. Symptoms and problems in a nationally representative sample of advanced cancer patients. Palliat Med. 2009;23(6):491-501.
14. Kim JEE, Dodd MJ, Aouizerat BE, Jahan T, Miaskowski C. A review of the prevalence and impact of multiple symptoms in oncology patients. J Pain Symptom Manage. 2009;37(4):715-736.
15. Linden W, Vodermaier A, Mackenzie R, Greig D. Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age. J Affect Disord. 2012;141(2-3):343-351.
16. Rangwala F, Zafar SY, Abernethy AP. Gastrointestinal symptoms in cancer patients with advanced disease: new methodologies, insights, and a proposed approach. Curr Opin Support Palliat Care. 2012;6(1):69-76.
17. Center for Medical Technology Policy. Recommendations for incorporating patient-reported outcomes (PROs) into clinical comparative effectiveness research (CER) in adult oncology. http://www.cmtpnet.org/ docs/resources/PRO-EGD.pdf. Accessed April 30, 2013.
18. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. http://www.fda. gov/downloads/Drugs/Guidances/UCM193282.pdf. Accessed April 30, 2013.
19. PCORI. PCORI methodology standards. http://www.pcori.org/assets/ PCORI-Methodology-Standards.pdf. Accessed April 30, 2013.
20. NQF. Patient-reported outcomes in performance measurement. http:// www.qualityforum.org/Publications/2012/12/Patient-Reported- Outcomes-in-Performance-Measurement.aspx. Accessed April 30, 2013.
21. Basch E, Abernethy AP, Mullins CD, et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol. 2012;30(34):4249-4255.
22. Reeve BB, Wyrwich KW, Wu AW, et al. ISOQOL recommends minimum standards for patient-reported outcome measures used in patientcentered outcomes and comparative effectiveness research. Qual Life Res. 2013;22(8):1889-1905.
23. Ahmed S, Berzon RA, Revicki DA, et al. The use of patient-reported outcomes (PRO) within comparative effectiveness research: implications for clinical practice and health care policy. Med Care. 2012;50(12):1060-1070.
24. Reilly CM, Bruner DW, Mitchell SA, et al. A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment. Support Care Cancer. 2013;21(6):1525-1550.
25. McCorkle R, Young K. Development of a symptom distress scale. Cancer Nurs. 1978;1(5):373-378.
26. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000;89(7):1634-1646.
27. Portenoy RK, Thaler HT, Kornblith AB, et al. The Memorial Symptom Assessment Scale: An instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer. 1994;30A(9):1326-1336.
28. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365-376.
29. European Organisation for Research and Treatment of Cancer Quality of Life Group. EORTC QLQ-C30 reference values. http://groups.eortc.be/ qol/sites/default/files/img/newsletter/reference-values-manual2008.pdf. Accessed January 25, 2013.
30. Cella D, Rosenbloom SK, Beaumont JL, et al. Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. J Natl Compr Canc Netw. 2011;9(3):268-278.
31. Bruner DW, Hanisch LJ, Reeve BB, et al. Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PROCTCAE). Transl Behav Med. 2011;1(1):110-122.
32. Fisch MJ, Lee JW, Weiss M, et al. Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol. 2012;30(16):1980-1988.
33. Bruner DW. Outcomes research in cancer symptom management trials: the Radiation Therapy Oncology Group (RTOG) conceptual model. J Natl Cancer Inst Monogr. 2007;2007(37):12-15.
34. Lipscomb J, Donaldson MS, Hiatt RA. Cancer outcomes research and the arenas of application. J Natl Cancer Inst Monogr. 2004;2004(33):1-7.
35. Bruner DW, Bryan CJ, Aaronson N, et al. Issues and challenges with integrating patient-reported outcomes in clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. J Clin Oncol. 2007;25(32):5051-5057.
36. Cleeland CS, Sloan JA, Cella D, et al. Recommendations for including multiple symptoms as endpoints in cancer clinical trials: A report from the ASCPRO (Assessing the Symptoms of Cancer Using Patient-Reported Outcomes) Multisymptom Task Force. Cancer. 2013;119(2):411-420.
37. Howell D, Fitch M, Bakker D, et al. Core domains for a person-focused outcome measurement system in cancer (PROMS-Cancer Core) for routine care: A scoping review and Canadian Delphi Consensus. Value Health. 2013;16(1):76v87.
38. Macefield RC, Avery KN, Blazeby JM. Integration of clinical and patientreported outcomes in surgical oncology. Br J Surg. 2013;100(1):28-37.
39. Williamson PR, Altman DG, Blazeby JM, et al. Developing core outcome sets for clinical trials: issues to consider. Trials. 2012;13:132.
40. Brundage M, Blazeby J, Revicki D, et al. Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards. Qual Life Res. 2013;22(6):1161-1175.
41. Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-822.
42. Kyte DG, Draper H, Ives J, Liles C, Gheorghe A, Calvert M. Patient reported outcomes (PROs) in clinical trials: is "in-trial" guidance lacking? A systematic review. PLoS One. 2013;8(4):e60684.
43. Brundage M, Osoba D, Bezjak A, et al. Lessons learned in the assessment of health-related quality of life: selected examples from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(32):5078-5081.
44. Bottomley A, Aaronson NK, European Organisation for Research and Treatment of Cancer. International perspective on health-related quality-oflife research in cancer clinical trials; the European Organisation for Research and Treatment of Cancer experience. J Clin Oncol. 2007;25(32):5082-5086.
45. Reeve BB, Withycombe JS, Baker JN, et al. The first step to integrating the child's voice in adverse event reporting in oncology trials: A content validation study among pediatric oncology clinicians. Pediatr Blood Cancer. 2013;60(7):1231-1236.
46. Kenna HA, Poon AW, de los Angeles CP, et al. Psychiatric complications of treatment with corticosteroids: review with case report. Psychiatry Clin Neurosci. 2011;65(6):549-560.
47. Sjoquist KM, Friedlander ML, O'Connell RL, et al. Hope, quality of life, and benefit from treatment in women having chemotherapy for platinumresistant/ refractory recurrent ovarian cancer: the gynecologic cancer intergroup symptom benefit study. Oncologist. 2013;18(11):1221-1228.
48. Hoppe S, Rainfray M, Fonck M, et al. Functional decline in older patients with cancer receiving first-line chemotherapy. J Clin Oncol. 2013;31(31):3877-3882.
49. Joseph LA, Routledge JA, Burns MP, et al. Value of the Hospital Anxiety and Depression Scale in the follow up of head and neck cancer patients. J Laryngol Otol. 2013;127(3):285-294.
50. Donovan KA, Donovan HS, Cella D, et al. Recommended patientreported core set of symptoms and other quality of life domains to measure in ovarian cancer treatment trials. J Natl Cancer Inst. 2014;106(7): dju128 doi:10.1093/jnci/dju128.
51. Chen RC, Chang P, Vetter RJ, et al. Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials. J Natl Cancer Inst. 2014;106(7): dju132 doi:10.1093/jnci/dju132.
52. Chera BS, Eisbruch A, Murphy BA, et al. Recommended patient-reported core set of symptoms to measure in head and neck cancer treatment trials. J Natl Cancer Inst. 2014;106(7): dju127 doi:10.1093/jnci/dju127.
53. Kaasa S, Loge JH, Fayers P, et al. Symptom assessment in palliative care: A need for international collaboration. J Clin Oncol. 2008;26(23):3867-3873.
54. Kirkova J, Davis MP, Walsh D, et al. Cancer symptom assessment instruments: A systematic review. J Clin Oncol. 2006;24(9):1459-1473.
55. Cleeland CS, Sloan JA, ASCPRO Organizing Group. Assessing the Symptoms of Cancer Using Patient-Reported Outcomes (ASCPRO): searching for standards. J Pain Symptom Manage. 2010;39(6):1077-1085.
56. Kirkova J, Aktas A, Walsh D, Davis MP. Cancer symptom clusters: clinical and research methodology. J Palliat Med. 2011;14(10):1149-1166.
57. Nguyen J, Cramarossa G, Bruner D, et al. A literature review of symptom clusters in patients with breast cancer. Expert Rev Pharmacoecon Outcomes Res. 2011;11(5):533-539.
58. Wyrwich KW, Norquist JM, Lenderking WR, Acaster S, ISOQOL. Methods for interpreting change over time in patient-reported outcome measures. Qual Life Res. 2013;22(3):475-483.
59. Hinds PS, Schum L, Srivastava DK. Is clinical relevance sometimes lost in summative scores? West J Nurs Res. 2002;24(4):345-353.
60. Hagen NA, Biondo PD, Brasher PM, Stiles CR. Formal feasibility studies in palliative care: why they are important and how to conduct them. J Pain Symptom Manage. 2011;42(2):278-289.
61. Rolstad S, Adler J, Ryden A. Response burden and questionnaire length: is shorter better? A review and meta-analysis. Value Health. 2011;14(8):1101-1108.
62. Basch E, Iasonos A, Barz A, et al. Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol. 2007;25(34):5374-5380.
63. Hjermstad MJ, Lie HC, Caraceni A, et al. Computer-based symptom assessment is feasible in patients with advanced cancer: results from an international multicenter study, the EPCRC-CSA. J Pain Symptom Manage. 2012;44(5):639-654.
64. Khanna D, Krishnan E, Dewitt EM, Khanna PP, Spiegel B, Hays RD. The future of measuring patient-reported outcomes in rheumatology: Patient-Reported Outcomes Measurement Information System (PROMIS). Arthritis Care Res (Hoboken). 2011;63(S11):S486-S490.
65. Meyers FJ, Linder J, Beckett L, Christensen S, Blais J, Gandara DR. Simultaneous care: A model approach to the perceived conflict between investigational therapy and palliative care. J Pain Symptom Manage. 2004;28(6):548-556